{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:17:45Z","timestamp":1721953065771},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,25]]},"DOI":"10.7759\/cureus.65368","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T16:32:25Z","timestamp":1721925145000},"source":"Crossref","is-referenced-by-count":0,"title":["Sustained Delivery of Rifampicin Nanoformulation Administration Intravitreally Into Rabbit Eyes for Ocular Tuberculosis"],"prefix":"10.7759","author":[{"given":"Rohitash","family":"Yadav","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chakrmani","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avaneesh","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritika","family":"Kondel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nushrat","family":"Shafiq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S65254","article-title":"Ocular tuberculosis: current perspectives","volume":"9","author":"Shakarchi FI","year":"2015","unstructured":"Shakarchi FI. Ocular tuberculosis: current perspectives. Clin Ophthalmol. 2015, 9:2223-7. 10.2147\/OPTH.S65254","journal-title":"Clin Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00347-020-01099-1","article-title":"Treatment of ocular tuberculosis-an update","volume":"117","author":"Br\u00f6nnimann LC","year":"2020","unstructured":"Br\u00f6nnimann LC, Zimmerli S, Garweg JG. Treatment of ocular tuberculosis-an update. Ophthalmologe. 2020, 117:1080-6. 10.1007\/s00347-020-01099-1","journal-title":"Ophthalmologe"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.256933","article-title":"Ocular drug delivery: present innovations and future challenges","volume":"370","author":"Gote V","year":"2019","unstructured":"Gote V, Sikder S, Sicotte J, Pal D. Ocular drug delivery: present innovations and future challenges. J Pharmacol Exp Ther. 2019, 370:602-24. 10.1124\/jpet.119.256933","journal-title":"J Pharmacol Exp Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-010-9183-3","article-title":"Ocular drug delivery","volume":"12","author":"Gaudana R","year":"2010","unstructured":"Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010, 12:348-60. 10.1208\/s12248-010-9183-3","journal-title":"AAPS J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpx.2023.100228","article-title":"Formulation, optimization and evaluation of ocular gel containing nebivolol Hcl-loaded ultradeformable spanlastics nanovesicles: In vitro and in vivo studies","volume":"7","author":"Yasser M","year":"2024","unstructured":"Yasser M, El Naggar EE, Elfar N, Teaima MH, El-Nabarawi MA, Elhabal SF. Formulation, optimization and evaluation of ocular gel containing nebivolol Hcl-loaded ultradeformable spanlastics nanovesicles: In vitro and in vivo studies. Int J Pharm X. 2024, 7:100228. 10.1016\/j.ijpx.2023.100228","journal-title":"Int J Pharm X"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S447429","article-title":"Nanosuspension-based drug delivery systems for topical applications","volume":"19","author":"Aldeeb MM","year":"2024","unstructured":"Aldeeb MM, Wilar G, Suhandi C, Elamin KM, Wathoni N. Nanosuspension-based drug delivery systems for topical applications. Int J Nanomedicine. 2024, 19:825-44. 10.2147\/IJN.S447429","journal-title":"Int J Nanomedicine"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2217\/nnm-2018-0258","article-title":"Matryoshka-type gastro-resistant microparticles for the oral treatment of Mycobacterium tuberculosis","volume":"14","author":"Andreu V","year":"2019","unstructured":"Andreu V, Larrea A, Rodriguez-Fernandez P, et al.. Matryoshka-type gastro-resistant microparticles for the oral treatment of Mycobacterium tuberculosis. Nanomedicine (Lond). 2019, 14:707-26. 10.2217\/nnm-2018-0258","journal-title":"Nanomedicine (Lond)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2016.03.024","article-title":"Rifapentine-loaded PLGA microparticles for tuberculosis inhaled therapy: Preparation and in vitro aerosol characterization","volume":"88","author":"Parumasivam T","year":"2016","unstructured":"Parumasivam T, Leung SS, Quan DH, Triccas JA, Britton WJ, Chan HK. Rifapentine-loaded PLGA microparticles for tuberculosis inhaled therapy: Preparation and in vitro aerosol characterization. Eur J Pharm Sci. 2016, 88:1-11. 10.1016\/j.ejps.2016.03.024","journal-title":"Eur J Pharm Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/09205063.2022.2144791","article-title":"Approaches for designing and delivering solid lipid nanoparticles of distinct antitubercular drugs","volume":"34","author":"Vasam M","year":"2023","unstructured":"Vasam M, Goulikar RK. Approaches for designing and delivering solid lipid nanoparticles of distinct antitubercular drugs. J Biomater Sci Polym Ed. 2023, 34:828-43. 10.1080\/09205063.2022.2144791","journal-title":"J Biomater Sci Polym Ed"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-49576-2","article-title":"Optimization, characterization, and cytotoxicity studies of novel anti-tubercular agent-loaded liposomal vesicles","volume":"14","author":"Obiedallah MM","year":"2024","unstructured":"Obiedallah MM, Mironov MA, Belyaev DV, et al.. Optimization, characterization, and cytotoxicity studies of novel anti-tubercular agent-loaded liposomal vesicles. Sci Rep. 2024, 14:524. 10.1038\/s41598-023-49576-2","journal-title":"Sci Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2005.07.012","article-title":"Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis","volume":"26","author":"Ahmad Z","year":"2005","unstructured":"Ahmad Z, Sharma S, Khuller GK. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents. 2005, 26:298-303. 10.1016\/j.ijantimicag.2005.07.012","journal-title":"Int J Antimicrob Agents"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/nano10071403","article-title":"Polymeric nanoparticles for drug delivery: recent developments and future prospects","volume":"10","author":"Begines B","year":"2020","unstructured":"Begines B, Ortiz T, P\u00e9rez-Aranda M, Mart\u00ednez G, Merinero M, Arg\u00fcelles-Arias F, Alcudia A. Polymeric nanoparticles for drug delivery: recent developments and future prospects. Nanomaterials (Basel). 2020, 10:10.3390\/nano10071403","journal-title":"Nanomaterials (Basel)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S257758","article-title":"Development of rifapentine-loaded PLGA-based nanoparticles: in vitro characterisation and in vivo study in mice","volume":"15","author":"Liang Q","year":"2020","unstructured":"Liang Q, Xiang H, Li X, et al.. Development of rifapentine-loaded PLGA-based nanoparticles: in vitro characterisation and in vivo study in mice. Int J Nanomedicine. 2020, 15:7491-507. 10.2147\/IJN.S257758","journal-title":"Int J Nanomedicine"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3109\/10717544.2010.509367","article-title":"Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis","volume":"18","author":"Kumar G","year":"2011","unstructured":"Kumar G, Sharma S, Shafiq N, Pandhi P, Khuller GK, Malhotra S. Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis. Drug Deliv. 2011, 18:65-73. 10.3109\/10717544.2010.509367","journal-title":"Drug Deliv"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3109\/02652048.2011.615948","article-title":"In\u00a0vitro physicochemical characterization and short term in\u00a0vivo tolerability study of ethionamide loaded PLGA nanoparticles: potentially effective agent for multidrug resistant tuberculosis","volume":"28","author":"Kumar G","year":"2011","unstructured":"Kumar G, Malhotra S, Shafiq N, Pandhi P, Khuller GK, Sharma S. In\u00a0vitro physicochemical characterization and short term in\u00a0vivo tolerability study of ethionamide loaded PLGA nanoparticles: potentially effective agent for multidrug resistant tuberculosis. J Microencapsul. 2011, 28:717-28. 10.3109\/02652048.2011.615948","journal-title":"J Microencapsul"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15875","article-title":"Bio-evaluation of poly(lactic-co-glycolic) acid nanoparticles loaded with radiolabelled rifampicin","volume":"89","author":"Rather I","year":"2023","unstructured":"Rather I, Shafiq N, Shukla J, et al.. Bio-evaluation of poly(lactic-co-glycolic) acid nanoparticles loaded with radiolabelled rifampicin. Br J Clin Pharmacol. 2023, 89:3702-14. 10.1111\/bcp.15875","journal-title":"Br J Clin Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-01992-2","article-title":"Nanotechnology-based ocular drug delivery systems: recent advances and future prospects","volume":"21","author":"Li S","year":"2023","unstructured":"Li S, Chen L, Fu Y. Nanotechnology-based ocular drug delivery systems: recent advances and future prospects. J Nanobiotechnology. 2023, 21:232. 10.1186\/s12951-023-01992-2","journal-title":"J Nanobiotechnology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e17488","article-title":"Advances in drug delivery systems, challenges and future directions","volume":"9","author":"Ezike TC","year":"2023","unstructured":"Ezike TC, Okpala US, Onoja UL, et al.. Advances in drug delivery systems, challenges and future directions. Heliyon. 2023, 9:e17488. 10.1016\/j.heliyon.2023.e17488","journal-title":"Heliyon"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2017.07.019","article-title":"Recent advances in nanoparticle-mediated drug delivery","volume":"41","author":"Kumar B","unstructured":"Kumar B, Jalodia K, Kumar P, Gautam HK. Recent advances in nanoparticle-mediated drug delivery. J Drug Deliv Sci Technol. 20171. 41:260-8. 10.1016\/j.jddst.2017.07.019","journal-title":"J Drug Deliv Sci Technol. 20171"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14122728","article-title":"PLGA-based nanomedicine: history of advancement and development in clinical applications of multiple diseases","volume":"14","author":"Alsaab HO","year":"2022","unstructured":"Alsaab HO, Alharbi FD, Alhibs AS, et al.. PLGA-based nanomedicine: history of advancement and development in clinical applications of multiple diseases. Pharmaceutics. 2022, 14:10.3390\/pharmaceutics14122728","journal-title":"Pharmaceutics"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/ma14226812","article-title":"Polymer-Based Nanosystems-A Versatile Delivery Approach","author":"Niculescu AG","year":"2021","unstructured":"Niculescu AG, Grumezescu AM. Polymer-Based Nanosystems-A Versatile Delivery Approach. 2021. 10.3390\/ma14226812"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S207978","article-title":"Issues with intravitreal administration of anti-VEGF drugs","volume":"14","author":"Schargus M","year":"2020","unstructured":"Schargus M, Frings A. Issues with intravitreal administration of anti-VEGF drugs. Clin Ophthalmol. 2020, 14:897-904. 10.2147\/OPTH.S207978","journal-title":"Clin Ophthalmol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/265650-sustained-delivery-of-rifampicin-nanoformulation-administration-intravitreally-into-rabbit-eyes-for-ocular-tuberculosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T16:32:29Z","timestamp":1721925149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/265650-sustained-delivery-of-rifampicin-nanoformulation-administration-intravitreally-into-rabbit-eyes-for-ocular-tuberculosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.65368","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,25]]}}}